EGFR and non-small cell lung carcinoma: TP53 mutations are the most common concurrent mutations in NSCLC, accounting for 30–72%, and are associated with poor clinical outcomes with EGFR-TKI therapy.24–28 In our cohort, we found statistically similar PFS outcomes between patients with wild-type TP53 and those who harbor TP53 mutations, even those located in exons 5–8 (Supplementary Fig. S5a), indicating that mefatinib might be a more suitable therapeutic option for patients with concurrent TP53 mutation.